Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:Guideline-based treatment recommendations and their limitationsData describing the relationship between viral suppression and HBV DNA integrationMore expansive indications for HBV treatment based on virologic considerationsPresenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related